ibusinesslines.com July 17, 2018

Price Target Estimates for Flexion Therapeutics, Inc. (FLXN)

11 October 2017, 03:48 | Myron Mathis

Price Target Estimates for Flexion Therapeutics, Inc. (FLXN)

Flexion Therapeutics Just Hit A Major Milestone

Macquarie Group Ltd. now owns 55,917 shares of the specialty pharmaceutical company's stock valued at $1,131,000 after purchasing an additional 338 shares during the last quarter. BMO Capital Markets' target price indicates a potential upside of 23.62% from the company's previous close. Zacks Investment Research cut Flexion Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, July 13th.

03/23/2017 - Flexion Therapeutics Inc had its "overweight" rating reiterated by analysts at Cantor Fitzgerald.

President and CEO, Clayman Michael D., purchased 5,000 common shares of Flexion Therapeutics, Inc. Tracking the stock price in relation to moving averages as well as highs and lows for the year might assist with evaluating future stock performance. Of those analysts, 4 rate stock as a Strong Buy, 0 rate it as Hold, and just no analyst rates it as a Moderate Sell. They may also be used to assist the trader figure out proper support and resistance levels for the stock.

Analysts expect Flexion Therapeutics Inc (NASDAQ:FLXN) to report $-0.95 EPS on November, 6.They anticipate $0.30 EPS change or 46.15% from last quarter's $-0.65 EPS. The relative volume of the stock is 12.94, while its market cap is $952.55 Million.

The most recent open market insider trade was Buy of 1,000 shares on a day where the closing price was 24.2.

Flexion Therapeutics has a 52 week low of $15.93 and a 52 week high of $32.25 FLXN's total market value is presently $0.

Flexion Therapeutics (NASDAQ:FLXN) last posted its quarterly earnings data on Tuesday, August 8th.

Among 3 analysts covering AMN Healthcare (NYSE:AMN), 2 have Buy rating, 0 Sell and 1 Hold. Comparatively, Flexion Therapeutics, Inc. posted earnings of $-0.82 per share in the same quarter past year. "(FLXN)" was originally posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this article on another publication, it was illegally copied and republished in violation of global copyright and trademark law. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2017/10/09/flexion-therapeutics-inc-flxn-pt-raised-to-37-00-at-bmo-capital-markets.html.

12/22/2016 - Raymond James began new coverage on Flexion Therapeutics Inc giving the company a "strong buy" rating. Over the last three months, insiders purchased 5,375 shares of company stock valued at $131,575. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company's stock valued at $441,000 after purchasing an additional 811 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: "Janney Montgomery Scott Boosts Flexion Therapeutics, Inc". Janney Montgomery Scott LLC now owns 17,970 shares of the specialty pharmaceutical company's stock valued at $363,000 after acquiring an additional 4,395 shares during the period. Guggenheim Capital LLC acquired a new stake in Flexion Therapeutics during the fourth quarter worth $1,326,000. Short interest grew 367,303 over that period. Unusual volume shows something has likely happened in the stock-such as a news release or traders have become anxious or euphoric about the stock's potential. Finally, The Manufacturers Life Insurance Company raised its position in Flexion Therapeutics by 3.9% during the second quarter.

Analysts' ultimate objective when projecting revenue is to determine the appropriate value for a stock. Company insiders own 15.98% of the company's stock.

Looking further out, over the past twelve months, Flexion Therapeutics, Inc.'s stock was 41.27% and 27.44% over the last quarter and 6.09% for the past six months. The Firm is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis.

Other News

Trending Now

Young Yankees force decisive Game 5
Tanaka most recently struck out 15 over seven scoreless innings against Toronto, ending an up-and-down regular season. Brett Gardner, Aaron Judge , Didi Gregorius, Jacoby Ellsbury and Chase Headley went a combined 0-19 on Friday night.

Donald Trump is acting like a fifth-grade bully
And if the American body politic doesn't experience a complete meltdown this week, perhaps others will notice. On Oct. 10, Trump took to social media to blast an interview that Corker had given to The New York Times .

11-year-old Utah girl learns her adoption is final
A video of an 11-year-old girl's reaction to learning she will be adopted by her foster family went viral, according to KUTV-TV . Alexander thought the moment was so attractive that she got Fisher's permission and shared the video on social media.

CBS clarifies statement on whether Colin Kaepernick would stand for national anthem
He did so in protest of police violence towards African-Americans around the country. He also plans to donate the money from his jersey sales to charity.

Swiss Police arrest 2 men after Marseille knife attack
He was shot and killed by police shortly after his rampage, which was claimed by the Islamic State (IS) terrorist group. In addition she would not confirm whether an global arrest warrant had been issued.

Bump-Stock Maker Hit With Lawsuit Following Las Vegas Massacre
Efforts to reach Slide Fire Solutions, which is based in Moran, Texas, were unsuccessful Tuesday. Fostech said it was suspending sales "until manufacturing can catch up with demand".

Dutch Legend Set To Retire After World Cup Elimination
The Netherlands needed to win by seven goals to have the chance to reach next year's World Cup in Russian Federation . Robben was part of the squads which finished third at the 2014 World Cup and lost the 2010 final to Spain.